Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefiderocol in infants < 3 months with Gram-negative infections
NCT06086626Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of cefiderocol in Gram-negative bacterial infection (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration After a Single Dose of Cefiderocol at 8 hours, Maximum Observed Plasma Concentration After a Minimum of 4 Doses of Cefiderocol at 8 hours and 4 more. Started Mar 2024; status: completed.
02
Drugs
cefiderocol
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT06086626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06086626.